Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
- PMID: 32685866
- PMCID: PMC7364850
- DOI: 10.1021/acsomega.0c02387
Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin
Abstract
A second-generation kilogram-scale synthesis of the psychedelic tryptamine psilocybin has been developed. The synthesis was designed to address several challenges first encountered with the scale-up of previously described literature procedures, which were not optimized for providing consistent yield and purity of products, atom economy, or being run in pilot plant-scale reactors. These challenges were addressed and circumvented with the design of the second-generation route, which featured an optimized cGMP large-scale Speeter-Anthony tryptamine synthesis to the intermediate psilocin with improved in-process control and impurity removal over the three steps. Psilocin was subsequently phosphorylated directly with phosphorous oxychloride for the first time, avoiding a tedious and poor atom economy benzyl-protecting group strategy common to all previously described methods for producing psilocybin. In this report, the challenges encountered in a 100 g scale first-generation literature-based synthesis are highlighted, followed by a detailed description of the newly developed second-generation synthesis to provide over one kilogram of high-purity psilocybin under cGMP.
Copyright © 2020 American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
Figures



References
-
- Carhart-Harris R. L.; Bolstridge M.; Rucker J.; Day C. M.; Erritzoe D.; Kaelen M.; Bloomfield M.; Rickard J. A.; Forbes B.; Feilding A.; et al. Psilocybin With Psychological Support For Treatment-Resistant Depression: An Open-Label Feasibility Study. Lancet Psychiat. 2016, 3, 619–627. 10.1016/S2215-0366(16)30065-7. - DOI - PubMed
-
- Griffiths R. R.; Johnson M. W.; Carducci M. A.; Umbricht A.; Richards W. A.; Richards B. D.; Cosimano M. P.; Klinedinst M. A. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 2016, 30, 1181–1197. 10.1177/0269881116675513. - DOI - PMC - PubMed
-
- Ross S.; Bossis A.; Guss J.; Agin-Liebes G.; Malone T.; Cohen B.; Mennenga S. E.; Belser A.; Kalliontzi K.; Babb J.; et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 2016, 30, 1165–1180. 10.1177/0269881116675512. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources